In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases

Current Drug Metabolism

Volumn 14, Issue 3, 2013, Pages 279-290

  Fioretti, Daniela ^a   Iurescia, Sandra ^a   Fazio, Vito Michele ^b,c   Rinaldi, Monica ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Cancer; Clinical studies; DNA electrotransfer; Electroimmunotherpay; Electrovaccination; Neurodegenerative diseases

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMEP; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA; DNA VACCINE; DOPACHROME TAUTOMERASE; GAMMA INTERFERON; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 12 PLASMID DNA VACCINE; MELANOMA ANTIGEN; MELANOMA VACCINE; P.DOM PSMA27 VACCINE; P.DOM WT1-126 VACCINE; P.DOM WT1-37 VACCINE; PLACEBO; PLASMID DNA; PVAXRCPSAV531 DNA VACCINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SCIB1 VACCINE; TETANUS TOXIN; TETWTCEA DNA VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VGX 3100; WART VIRUS VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CELL ORGANELLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRIC FIELD; ELECTRODE; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC ALGORITHM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; MULTICENTER STUDY (TOPIC); NEEDLE; NONHUMAN; ONCOLOGY; PAPILLOMAVIRUS INFECTION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SKIN CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ANIMALS; DNA; ELECTROCHEMOTHERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84877950434     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314030003     Document Type: Review

References (140)

1. Escoffre, J. M.; Portet, T.; Wasungu, L.; Teissie, J.; Dean, D.; Rols, M. P. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues? Mol. Biotechnol., 2009, 4 (3), 286-295.
2. Miklavcic, D.; Semrov, D.; Mekid, H.; Mir, L. M. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim. Biophys. Acta, 2000, 1523 (1), 73-83.
3. Mir, L. M. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochem., 2001, 53 (1), 1-10. (Pubitemid 32015625)
4. Mir, L. M.; Bureau, M. F.; Gehl, J.; Rangara, R.; Rouy, D.; Caillaud, J. M.; Delaere, P.; Branellec, D.; Schwartz, B.; Scherman, D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96 (8), 4262-4267. (Pubitemid 29190324)
5. Marty, M.; Sersa, G.; Garbay, J.; Gehl, J.; Collins, C.; Snoj, M.; Billard, V.; Geertsen, P.; Larkin, J.; Miklavcic, D.; Pavlovic, I.; Paulin-Kosir, S.; Cemazar, M.; Morsli, N.; Rudolf, Z.; Robert, C.; O'Sullivan, G.; Mir, L. M. Electrochemotherapy-An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur. J. Cancer. Suppl., 2006, 4, 3-13. (Pubitemid 44755131)
6. Gehl, J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta. Physiol. Scand., 2003, 177 (4), 437-447. (Pubitemid 36411581)
7. Gothelf, A.; Mir, L. M.; Gehl, J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev., 2003, 29 (5), 371-387. (Pubitemid 37185104)
8. Mir, L. M.; Glass, L. F.; Sersa, G.; Teissie, J.; Domenge, C.; Miklavcic, D.; Jaroszeski, M. J.; Orlowski, S.; Reintgen, D. S.; Rudolf, Z.; Belehradek, M.; Gilbert, R.; Rols, M. P.; Belehradek, J., Jr.; Bachaud, J. M.; DeConti, R.; Stabuc, B.; Cemazar, M.; Coninx, P.; Heller, R. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br. J. Cancer., 1998, 77 (12), 2336-2342. (Pubitemid 28263963)
9. Sersa, G.; Miklavcic, D.; Cemazar, M.; Rudolf, Z.; Pucihar, G.; Snoj, M. Electrochemotherapy in treatment of tumours. Eur. J. Surg. Oncol., 2008, 34 (2), 232-240.
10. Corovic, S.; Zupanic, A.; Kranjc, S.; Al Sakere, B.; Leroy-Willig, A.; Mir, L. M.; Miklavcic, D. The influence of skeletal muscle anisotropy on electroporation: in vivo study and numerical modeling. Med. Biol. Eng. Comput., 2010, 48 (7), 637-648.
11. Neumann, E.; Rosenheck, K. Permeability changes induced by electric impulses in vesicular membranes. J. Membr. Biol., 1972, 10 (3), 279-290.
12. Escoffre, J. M.; Dean, D. S.; Hubert, M.; Rols, M. P.; Favard, C. Membrane perturbation by an external electric field: a mechanism to permit molecular uptake. Eur. Biophys. J., 2007, 36 (8), 973-983. (Pubitemid 350045043)
13. Vandermeulen, G.; Staes, E.; Vanderhaeghen, M. L.; Bureau, M. F.; Scherman, D.; Preat, V. Optimisation of intradermal DNA electrotransfer for immunisation. J. Control. Release, 2007, 124 (1-2), 81-87. (Pubitemid 350088207)
14. Isaka, Y.; Yamada, K.; Takabatake, Y.; Mizui, M.; Miura-Tsujie, M.; Ichimaru, N.; Yazawa, K.; Utsugi, R.; Okuyama, A.; Hori, M.; Imai, E.; Takahara, S. Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther., 2005, 12 (10), 815-820. (Pubitemid 40753973)
15. Zhou, R.; Norton, J. E.; Zhang, N.; Dean, D. A. Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and inflammation. Gene Ther., 2007, 14 (9), 775-780. (Pubitemid 46585659)
16. Liu, F.; Huang, L. Electric gene transfer to the liver following systemic administration of plasmid DNA. Gene Ther., 2002, 9 (16), 1116-1169.
17. Golzio, M.; Mazzolini, L.; Moller, P.; Rols, M. P.; Teissie, J. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther.,2005, 12 (3), 246-251. (Pubitemid 40220626)
18. Dean, D. A. Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals. Am. J. Physiol. Cell. Physiol., 2005, 289 (2), C233-245. (Pubitemid 41008869)
19. Tupin, E.; Poirier, B.; Bureau, M. F.; Khallou-Laschet, J.; Vranckx, R.; Caligiuri, G.; Gaston, A. T.; Duong Van Huyen, J. P.; Scherman, D.; Bariety, J.; Michel, J. B.; Nicoletti, A. Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Ther., 2003, 10 (7), 569-579. (Pubitemid 36432608)
20. Saito, T.; Nakatsuji, N. Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. Dev. Biol., 2001, 240 (1), 237-246. (Pubitemid 33141120)
21. Bloquel, C.; Bejjani, R.; Bigey, P.; Bedioui, F.; Doat, M.; BenEzra, D.; Scherman, D.; Behar-Cohen, F. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB. J., 2006, 20 (2), 389-391. (Pubitemid 46671181)
22. Rols, M. P.; Delteil, C.; Golzio, M.; Dumond, P.; Cros, S.; Teissie, J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nature Biotechnol., 1998, 16 (2), 168-171. (Pubitemid 28078505)
23. Goto, T.; Nishi, T.; Tamura, T.; Dev, S. B.; Takeshima, H.; Kochi, M.; Yoshizato, K.; Kuratsu, J.; Sakata, T.; Hofmann, G. A.; Ushio, Y. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97 (1), 354-359. (Pubitemid 30055835)
24. Satkauskas, S.; Andre, F.; Bureau, M. F.; Scherman, D.; Miklavcic, D.; Mir, L. M. Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer. Hum. Gene Ther., 2005, 16 (10), 1194-1201. (Pubitemid 41443711)
25. Pavselj, N.; Preat, V. DNA electrotransfer into the skin using a combination of one high-and one low-voltage pulse. J. Control. Release, 2005, 106 (3), 407-415. (Pubitemid 41187449)
26. Jaichandran, S.; Yap, S. T.; Khoo, A. B.; Ho, L. P.; Tien, S. L.; Kon, O. L. In vivo liver electroporation:optimization and demonstration of therapeutic efficacy. Hum. Gene Ther., 2006, 17 (3), 362-375.
27. Hojman, P.; Zibert, J. R.; Gissel, H.; Eriksen, J.; Gehl, J. Gene expression profiles in skeletal muscle after gene electrotransfer. BMC. Mol. Biol., 2007, 8, 56.
28. Mathiesen, I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther., 1999, 6(4), 508-514. (Pubitemid 29192659)
29. Perez, N.; Bigey, P.; Scherman, D.; Danos, O.; Piechaczyk, M.; Pelegrin, M. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet. Vaccines Ther., 2004, 2 (1), 2.
30. Umeda, Y.; Marui, T.; Matsuno, Y.; Shirahashi, K.; Iwata, H.; Takagi, H.; Matsumoto, K.; Nakamura, T.; Kosugi, A.; Mori, Y.; Takemura, H. Skeletal muscle targeting in vivo electroporationmediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab. Invest., 2004, 84 (7), 836-844. (Pubitemid 38833243)
31. Scherman, D.; Bigey, P.; Bureau, M. F. Applications of plasmid electrotransfer. Technol. Cancer. Res. Treat. 2002, 1 (5), 351-354. (Pubitemid 36554393)
32. Bloquel, C.; Fabre, E.; Bureau, M. F.; Scherman, D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J. Gene. Med., 2004, 6 Suppl 1, S11-23. (Pubitemid 40228013)
33. Iurescia, S.; Fioretti, D.; Fazio, V. M.; Rinaldi, M. Design and preclinical development of epitope-based DNA vaccines against B-cell lymphoma. Curr. Gene Ther., 2011, 11 (5), 414-422.
34. Iurescia, S.; Fioretti, D.; Fazio, V. M.; Rinaldi, M. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: A biotech's challenge. Biotechnol. Adv., 2012, 30 (1), 372-383.
35. Iurescia, S.; Fioretti, D.; Pierimarchi, P.; Signori, E.; Zonfrillo, M.; Tonon, G.; Fazio, V. M.; Rinaldi, M. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J. Biomed. Biotechnol., 2010, 2010, 316069.
36. Rinaldi, M.; Fioretti, D.; Iurescia, S.; Signori, E.; Pierimarchi, P.; Seripa, D.; Tonon, G.; Fazio, V. M. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochem. Biophys. Res. Commun., 2008, 370 (2), 279-284.
37. Rice, J.; Ottensmeier, C. H.; Stevenson, F. K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer, 2008, 8 (2), 108-120. (Pubitemid 351161331)
38. Verma, I. M.; Weitzman, M. D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem., 2005, 74, 711-738. (Pubitemid 40995522)
39. Fazio, V. M.; Ria, F.; Franco, E.; Rosati, P.; Cannelli, G.; Signori, E.; Parrella, P.; Zaratti, L.; Iannace, E.; Monego, G.; Blogna, S.; Fioretti, D.; Iurescia, S.; Filippetti, R.; Rinaldi, M. Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization. Gene Ther., 2004, 11 (6), 544-551. (Pubitemid 38443521)
40. Rinaldi, M.; Catapano, A. L.; Parrella, P.; Ciafre, S. A.; Signori, E.; Seripa, D.; Uboldi, P.; Antonini, R.; Ricci, G.; Farace, M. G.; Fazio, V. M. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Ther., 2000, 7 (21), 1795-1801.
41. Rinaldi, M.; Ria, F.; Parrella, P.; Signori, E.; Serra, A.; Ciafre, S. A.; Vespignani, I.; Lazzari, M.; Farace, M. G.; Saglio, G.; Fazio, V. M. Antibodies elicited by naked DNA vaccination against the complementary- determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of Blymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res., 2001, 61 (4), 1555-1562. (Pubitemid 34292587)
42. Rinaldi, M.; Signori, E.; Rosati, P.; Cannelli, G.; Parrella, P.; Iannace, E.; Monego, G.; Ciafre, S. A.; Farace, M. G.; Iurescia, S.; Fioretti, D.; Rasi, G.; Fazio, V. M. Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety. Vaccine, 2006, 24 (21), 4586-4591. (Pubitemid 44218842)
43. Fioretti, D.; Iurescia, S.; Fazio, V. M.; Rinaldi, M. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol., 2010 DOI: 10.1155/2010/174378.
44. Lowe, D. B.; Shearer, M. H.; Jumper, C. A.; Kennedy, R. C. Towards progress on DNA vaccines for cancer. Cell Mol. Life. Sci., 2007, 64 (18), 2391-2403. (Pubitemid 47402584)
45. Rols, M. P. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim. Biophys. Acta., 2006, 1758 (3), 423-428.
46. Rols, M. P.; Teissie, J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys. J., 1990, 58 (5), 1089-1098. (Pubitemid 20363969)
47. Kotnik, T.; Miklavcic, D. Analytical description of transmembrane voltage induced by electric fields on spheroidal cells. Biophys. J., 2000, 79 (2), 670-679. (Pubitemid 30626164)
48. Hibino, M.; Shigemori, M.; Itoh, H.; Nagayama, K.; Kinosita, K., Jr. Membrane conductance of an electroporated cell analyzed by submicrosecond imaging of transmembrane potential. Biophys. J., 1991, 59 (1), 209-220.
49. Escoffre, J. M.; Teissie, J.; Rols, M. P. Gene transfer: how can the biological barriers be overcome? J. Membr. Biol., 2010, 236 (1), 61-74.
50. Golzio, M.; Teissie, J.; Rols, M. P. Cell synchronization effect on mammalian cell permeabilization and gene delivery by electric field. Biochem. Biophys. Acta., 2002, 1563 (1-2), 23-28. (Pubitemid 34455039)
51. Sukharev, S. I.; Klenchin, V. A.; Serov, S. M.; Chernomordik, L. V.; Chizmadzhev Yu, A. Electroporation and electrophoretic DNA transfer into cells. The effect of DNA interaction with electropores. Biophys. J., 1992, 63 (5), 1320-1327. (Pubitemid 23004481)
52. Tarek, M. Membrane electroporation: a molecular dynamics simulation. Biophys. J., 2005, 88 (6), 4045-4053. (Pubitemid 40991116)
53. Lechardeur, D.; Lukacs, G. L. Intracellular barriers to non-viral gene transfer. Curr. Gene Ther., 2002, 2 (2), 183-194.
54. Dowty, M. E.; Williams, P.; Zhang, G.; Hagstrom, J. E.; Wolff, J. A. Plasmid DNA entry into postmitotic nuclei of primary rat myotubes. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92 (10), 4572-4576.
55. Zupanic, A.; Corovic, S.; Miklavcic, D.; Pavlin, M. Numerical optimization of gene electrotransfer into muscle tissue. Biomed. Eng. Online, 2010, 9, 66.
56. Golzio, M.; Escoffre, J. M.; Portet, T.; Mauroy, C.; Teissie, J.; Dean, D. S.; Rols, M. P. Observations of the mechanisms of electromediated DNA uptake-from vesicles to tissues. Curr. Gene Ther., 2010, 10 (4), 256-266.
57. Miklavcic, D.; Beravs, K.; Semrov, D.; Cemazar, M.; Demsar, F.; Sersa, G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys. J., 1998, 74 (5), 2152-2158. (Pubitemid 28225212)
58. Pavelj, N.; Miklavi, D. Numerical modeling in electroporationbased biomedical applications. Radiol. Oncol., 2008, 42 (3), 159-168.
59. Susil, R.; Semrov, D.; Miklavcic, D. Electric Field-Induced Transmembrane Potential Depends on Cell Density and Organizatio. Electromagn. Biol. Med., 1998, 17 (3), 391-399.
60. Valic, B.; Golzio, M.; Pavlin, M.; Schatz, A.; Faurie, C.; Gabriel, B.; Teissie, J.; Rols, M. P.; Miklavcic, D. Effect of electric field induced transmembrane potential on spheroidal cells: theory and experiment. Eur. Biophys. J., 2003, 32 (6), 519-528. (Pubitemid 37408656)
61. Tjelle, T. E.; Salte, R.; Mathiesen, I.; Kjeken, R. A novel electroporation device for gene delivery in large animals and humans. Vaccine, 2006, 24 (21), 4667-4670. (Pubitemid 43776760)
62. Luxembourg, A.; Hannaman, D.; Ellefsen, B.; Nakamura, G.; Bernard, R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine, 2006, 24 (21), 4490-4493. (Pubitemid 43776784)
63. Van Drunen Littel-Van Den Hurk, S.; Hannaman, D. Electroporation for DNA immunization: clinical application. Expert Rev. Vaccines, 2010, 9 (5), 503-517.
64. Frelin, L.; Brass, A.; Ahlen, G.; Brenndorfer, E. D.; Chen, M.; Sallberg, M. Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect., 2010, 23 (10), 647-653.
65. ClinicalTrials.gov, Study of a DNA Immunotherapy to Treat Melanoma (NCT01138410). http://clinicaltrials.gov/ct2/show/study/NCT01138410 (accessed February 21, 2012).
66. ClinicalTrials.gov, WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (WIN) (NCT01334060). http://clinicaltrials.gov/ct2/show/ NCT01334060 (accessed February 21, 2012).
67. Chaise, C.; Buchan, S. L.; Rice, J.; Marquet, J.; Rouard, H.; Kuentz, M.; Vittes, G. E.; Molinier-Frenkel, V.; Farcet, J. P.; Stauss, H. J.; Delfau-Larue, M. H.; Stevenson, F. K. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood, 2008, 112 (7), 2956-2964.
68. ClinicalTrials.gov, A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003) (NCT01304524). http://clinicaltrials. gov/ct2/show/NCT01304524 (accessed February 21, 2012).
69. Heller, R.; Cruz, Y.; Heller, L. C.; Gilbert, R. A.; Jaroszeski, M. J. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum. Gene Ther., 2010, 21 (3), 357-362.
70. Roos, A. K.; Eriksson, F.; Walters, D. C.; Pisa, P.; King, A. D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol. Ther., 2009, 17 (9), 1637-1642.
71. Staff, C.; Mozaffari, F.; Haller, B. K.; Wahren, B.; Liljefors, M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine, 2011, 29 (39), 6817-6822.
72. ClinicalTrials.gov, Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer (ElporCEA) (NCT01064375). http://clinicaltrials.gov/ct2/show/study/NCT01064375 (accessed February 21, 2012).
73. Clinical Trials.gov, Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients with Prostate Cancer (NCT00859729). http://clinicaltrials.gov/ct2/show/NCT00859729 (accessed Feruary 21, 2012).
74. Prausnitz, M. R.; Mikszta, J. A.; Cormier, M.; Andrianov, A. K. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol., 2009, 333, 369-393.
75. Gill, H. S.; Soderholm, J.; Prausnitz, M. R.; Sallberg, M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther., 2010, 17 (6), 811-814.
76. Choi, S. O.; Kim, Y. C.; Park, J. H.; Hutcheson, J.; Gill, H. S.; Yoon, Y. K.; Prausnitz, M. R.; Allen, M. G. An electrically active microneedle array for electroporation. Biomed. Microdevices, 2010, 12 (2), 263-273.
77. Heller, L. C.; Heller, R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr. Gene Ther., 2010, 10 (4), 312-317.
78. Clinicaltrials.gov, Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma (NCT00323206). http://clinicaltrials. gov/ct2/show/ NCT00323206 (accessed February 16, 2012).
79. ClinicalTrials.gov, Trial of pIL-12 Electroporation Malignant Melanoma (NCT01502293). http://clinicaltrials.gov/ct2/show/NCT01502293 (accessed February 16, 2012).
80. Bouquet, C.; Dam, E.; Trochon-Joseph, V.; Polard, V.; Sainte-Catherine, V.; Soma, E.; Lebel-Binay., S. Biodistribution of plasmid AMEP, a potent antitumor gene product for the treatment of metastatic melanomas. Mol. Ther., 2010, 18 (Suppl.1), S42.
81. Bouquet, C.; Trochon-Joseph, V.; Polard, V.; Mir, L. M.; Perricaudet, M.; Lebel-Binay, S. Plasmid AMEP, a new efficient antitumor gene transfer product for the treatment of metastatic melanomas. Mol. Ther., 2010, 18 (Suppl.1), S329.
82. Bouquet, C.; Trochon-Joseph, V.; Polard, V.; Sainte-Catherine, V.; Soma, E.; Lebel-Binay., S. Toxicology and safety studies of plasmid AMEP, a new Efficient antitumor gene product for the treatment of metastatic melanomas. Mol. Ther., 2010, 18 (Suppl.1), S43.
83. ClinicalTrials.gov, Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma (NCT01045915). http://clinicaltrials.gov/ct2/show/NCT01045915 (accessed February 16, 2012).
84. Low, L.; Mander, A.; McCann, K.; Dearnaley, D.; Tjelle, T.; Mathiesen, I.; Stevenson, F.; Ottensmeier, C. H. DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Hum. Gene Ther., 2009, 20 (11), 1269-1278.
85. Dolter, K. E.; Evans, C. F.; Ellefsen, B.; Song, J.; Boente-Carrera, M.; Vittorino, R.; Rosenberg, T. J.; Hannaman, D.; Vasan, S. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine, 2011, 29 (4), 795-803.
86. Bregman, C. L.; Adler, R. R.; Morton, D. G.; Regan, K. S.; Yano, B. L. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP). Toxicol. Pathol., 2003, 31 (2), 252-253. (Pubitemid 36374016)
87. Ahlen, G.; Soderholm, J.; Tjelle, T.; Kjeken, R.; Frelin, L.; Hoglund, U.; Blomberg, P.; Fons, M.; Mathiesen, I.; Sallberg, M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J. Immunol., 2007, 179(7), 4741-4753.
88. Luckay, A.; Sidhu, M. K.; Kjeken, R.; Megati, S.; Chong, S. Y.; Roopchand, V.; Garcia-Hand, D.; Abdullah, R.; Braun, R.; Montefiori, D. C.; Rosati, M.; Felber, B. K.; Pavlakis, G. N.; Mathiesen, I.; Israel, Z. R.; Eldridge, J. H.; Egan, M. A. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol., 2007, 81 (10), 5257-5269. (Pubitemid 46744435)
89. Roos, A. K.; Eriksson, F.; Timmons, J. A.; Gerhardt, J.; Nyman, U.; Gudmundsdotter, L.; Brave, A.; Wahren, B.; Pisa, P. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One, 2009, 4 (9), e7226.
90. Brave, A.; Gudmundsdotter, L.; Sandstrom, E.; Haller, B. K.; Hallengard, D.; Maltais, A. K.; King, A. D.; Stout, R. R.; Blomberg, P.; Hoglund, U.; Hejdeman, B.; Biberfeld, G.; Wahren, B. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine, 2010, 28 (51), 8203-8209.
91. Martin, T.; Parker, S. E.; Hedstrom, R.; Le, T.; Hoffman, S. L.; Norman, J.; Hobart, P.; Lew, D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum. Gene Ther., 1999, 10 (5),759-768. (Pubitemid 29168160)
92. Sheets, R. L.; Stein, J.; Manetz, T. S.; Duffy, C.; Nason, M.; Andrews, C.; Kong, W. P.; Nabel, G. J.; Gomez, P. L. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol. Sci., 2006, 91 (2), 610-619. (Pubitemid 43827313)
93. Vilalta, A.; Mahajan, R. K.; Hartikka, J.; Leamy, V.; Martin, T.; Rusalov, D.; Bozoukova, V.; Lalor, P.; Hall, K.; Kaslow, D. C.; Rolland, A. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum. Gene Ther., 2005, 16 (10), 1151-1156. (Pubitemid 41443707)
94. Vilalta, A.; Mahajan, R. K.; Hartikka, J.; Rusalov, D.; Martin, T.; Bozoukova, V.; Leamy, V.; Hall, K.; Lalor, P.; Rolland, A.; Kaslow, D. C. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum. Gene Ther., 2005, 16 (10), 1143-1150. (Pubitemid 41443706)
95. Babiuk, S.; Baca-Estrada, M. E.; Foldvari, M.; Middleton, D. M.; Rabussay, D.; Widera, G.; Babiuk, L. A. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol., 2004, 110 (1), 1-10. (Pubitemid 38510249)
96. Heller, L. C.; Heller, R. In vivo electroporation for gene therapy. Hum. Gene Ther., 2006, 17 (9), 890-897. (Pubitemid 46076749)
97. Kutzler, M. A.; Weiner, D. B. DNA vaccines: ready for prime time? Nat .Rev. Genet., 2008, 9 (10), 776-788.
98. Liu, M. A. Immunologic basis of vaccine vectors. Immunity, 2010, 33 (4), 504-515.
99. Rochard, A.; Scherman, D.; Bigey, P. Genetic immunization with plasmid DNA mediated by electrotransfer. Hum. Gene Ther., 2011, 22 (7), 789-798.
100. Zanetti, M. T for two: when helpers need help. Autoimmun. Rev., 2005, 4 (8), 571-578. (Pubitemid 41415772)
101. Daud, A. I.; DeConti, R. C.; Andrews, S.; Urbas, P.; Riker, A. I.; Sondak, V. K.; Munster, P. N.; Sullivan, D. M.; Ugen, K. E.; Messina, J. L.; Heller, R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol., 2008, 26 (36), 5896-5903.
102. Heller, R.; Shirley, S.; Guo, S.; Donate, A.; Heller, L. In Electroporation based gene therapy-From the bench to the bedside: Engineering in Medicine and Biology Society (EMBC) 2011 Annual International Conference of the IEEE, Boston, MA. p.736-738 DOI 10.1109/IEMBS.2011.6090167 2011; pp 736-738.
103. ClinicalTrials.gov, A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma (NCT00223899). http://clinicaltrials.gov/ct2/show/NCT00223899 (accessed February, 16, 2012).
104. ClinicalTrials.gov, Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation (NCT00471133). http://clinicaltrials.gov/ct2/show/ NCT00471133 (accessed February 16, 2012).
105. ClinicalTrials.gov, Interleukin-12 Gene and in Vivo Electroporation- Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer (NCT01440816). http://clinicaltrials.gov/ct2/show/NCT01440816 (accessed February 16, 2012).
106. Worldwide, G. T. C. T., Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma Trial ID : US-1044. www.abedia.com/wiley/ record-detail.php?ID=1674 (accessed February 16, 2012).
107. Lu, J.; Celis, E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res., 2002, 62 (20), 5807-5812. (Pubitemid 35204739)
108. Ottensmeier, C.; Low, L.; Mander, A.; Williams, A.; Tjelle, T.; Campos-Perez, J.; Heath, C.; Dearnaley, D.; Mathiesen, I.; Stevenson, F. In DNA fusion gene vaccination, delivered with or without in vivo electroporation-A potent and safe strategy for inducing anti-tumor immune responses in prostate cancer, AACR Meeting Abstracts, p.300, 2008; p 300.
109. Ferraro, B.; Cisper, N. J.; Talbott, K. T.; Philipson-Weiner, L.; Lucke, C. E.; Khan, A. S.; Sardesai, N. Y.; Weiner, D. B. Codelivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum. Vaccines, 2011, 7 Suppl, 120-127.
110. Kenter, G. G.; Welters, M. J.; Valentijn, A. R.; Lowik, M. J.; Berends-Van der Meer, D. M.; Vloon, A. P.; Essahsah, F.; Fathers, L. M.; Offringa, R.; Drijfhout, J. W.; Wafelman, A. R.; Oostendorp, J.; Fleuren, G. J.; Van der Burg, S. H.; Melief, C. J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med., 2009, 361 (19), 1838-1847.
111. ClinicalTrials.gov, Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 (NCT00685412). http:// clinicaltrials.gov/ct2/show/NCT00685412 (accessed February 16, 2012).
112. Bodles-Brakhop, A. M.; Heller, R.; Draghia-Akli, R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol. Ther., 2009, 17 (4), 585-592.
113. Sardesai, N. Y. In DNA vaccine and immune therapy for cervical cancer, Cancer Vaccines/Adjuvants/Delivery for the Next Decade, Dublin, Ireland Dublin, Ireland 2009.
114. Sardesai, N. Y.; Weiner, D. B. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol., 2011, 23 (3), 421-429.
115. Trimble, C. L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T. C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin .Cancer. Res., 2009, 15 (1), 361-367.
116. Kolb, H. J.; Schattenberg, A.; Goldman, J. M.; Hertenstein, B.; Jacobsen, N.; Arcese, W.; Ljungman, P.; Ferrant, A.; Verdonck, L.; Niederwieser, D.; Van Rhee, F.; Mittermueller, J.; De Witte, T.; Holler, E.; Ansari, H.; European Group for, B.; Marrow Transplantation Working Party Chronic, L. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 1995, 86 (5), 2041-2050.
117. Greiner, J.; Dohner, H.; Schmitt, M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematolog., 2006, 91 (12),1653-1661. (Pubitemid 46039635)
118. Tebbutt, N. C.; Cattell, E.; Midgley, R.; Cunningham, D.; Kerr, D. Systemic treatment of colorectal cancer. Eur. J. Cancer., 2002, 38 (7), 1000-1015. (Pubitemid 34442328)
119. Dalerba, P.; Maccalli, C.; Casati, C.; Castelli, C.; Parmiani, G. Immunology and immunotherapy of colorectal cancer. Crit. Rev. Oncol. Hematol., 2003, 46 (1), 33-57. (Pubitemid 36369415)
120. Samanci, A.; Yi, Q.; Fagerberg, J.; Strigard, K.; Smith, G.; Ruden, U.; Wahren, B.; Mellstedt, H. Pharmacological administration of granulocyte/ macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer. Immunol. Immunother., 1998, 47 (3), 131-142. (Pubitemid 28518327)
121. Ullenhag, G. J.; Frodin, J. E.; Jeddi-Tehrani, M.; Strigard, K.; Eriksson, E.; Samanci, A.; Choudhury, A.; Nilsson, B.; Rossmann, E. D.; Mosolits, S.; Mellstedt, H. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer. Res., 2004, 10 (10), 3273-3281. (Pubitemid 38685431)
122. Shimamura, M.; Sato, N.; Morishita, R. Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Curr. Gene Ther., 2011, 11 (6), 491-500.
123. Frisardi, V.; Solfrizzi, V.; Imbimbo, P. B.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.; Panza, F. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res., 2010, 7 (1), 40-55.
124. Brody, D. L.; Holtzman, D. M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008, 31, 175-193.
125. Pride, M.; Seubert, P.; Grundman, M.; Hagen, M.; Eldridge, J.; Black, R. S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis., 2008, 5 (3-4), 194-196. (Pubitemid 351347848)
126. Orgogozo, J. M.; Gilman, S.; Dartigues, J. F.; Laurent, B.; Puel, M.; Kirby, L. C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B. F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61 (1), 46-54. (Pubitemid 36818745)
127. Qu, B.; Rosenberg, R. N.; Li, L.; Boyer, P. J.; Johnston, S. A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch. Neurol., 2004, 61 (12), 1859-1864. (Pubitemid 39612946)
128. Qu, B.; Boyer, P. J.; Johnston, S. A.; Hynan, L. S.; Rosenberg, R. N. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J. Neurol. Sci., 2006, 244 (1-2), 151-158.
129. Movsesyan, N.; Ghochikyan, A.; Mkrtichyan, M.; Petrushina, I.; Davtyan, H.; Olkhanud, P. B.; Head, E.; Biragyn, A.; Cribbs, D. H.; Agadjanyan, M. G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-A novel immunotherapeutic strategy. PLoS One ,2008, 3 (5), e2124.
130. Davtyan, H.; Ghochikyan, A.; Cadagan, R.; Zamarin, D.; Petrushina, I.; Movsesyan, N.; Martinez-Sobrido, L.; Albrecht, R. A.; Garcia-Sastre, A.; Agadjanyan, M. G. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J. Transl. Med., 2011, 9, 127.
131. Lambracht-Washington, D.; Qu, B. X.; Fu, M.; Eagar, T. N.; Stuve, O.; Rosenberg, R. N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA, 2009, 302 (16), 1796-1802.
132. Movsesyan, N.; Mkrtichyan, M.; Petrushina, I.; Ross, T. M.; Cribbs, D. H.; Agadjanyan, M. G.; Ghochikyan, A. DNA epitope vaccine containing complement component C3d enhances antiamyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J. Neuroimmunol., 2008, 205 (1-2), 57-63.
133. Davtyan, H.; Ghochikyan, A.; Movsesyan, N.; Ellefsen, B.; Petrushina, I.; Cribbs, D. H.; Hannaman, D.; Evans, C. F.; Agadjanyan, M. G. Delivery of a DNA Vaccine for Alzheimer's Disease by Electroporation versus Gene Gun Generates Potent and Similar Immune Responses. Neurodegener. Dis., 2012, 10 (1-4), 261-264.
134. Alzheimer's Disease Vaccines Laboratory-Anahit Ghochikyan, Ph.D. Head of the Alzheimer's Disease Vaccines Laboratory. http://www.immunimmed. org/Alzheimers-decease.html (accessed 21/02/2012.
135. Xing, X.; Sha, S.; Li, Y.; Zong, L.; Jiang, T.; Cao, Y. Immunization with a new DNA vaccine for Alzheimer's disease elicited Th2 immune response in BALB/c mice by in vivo electroporation. J. Neurol. Sci., 2011, 313 (1-2), 17-21.
136. Fissolo, N.; Montalban, X.; Comabella, M. DNA-based vaccines for multiple sclerosis: Current status and future directions. Clin. Immunol., 2010, 142 (1), 76-83.
137. Bar-Or, A.; Vollmer, T.; Antel, J.; Arnold, D. L.; Bodner, C. A.;
138. Garren, H.; Robinson, W. H.; Krasulova, E.; Havrdova, E.; Nadj, C.; Selmaj, K.; Losy, J.; Nadj, I.; Radue, E. W.; Kidd, B. A.; Gianettoni, J.; Tersini, K.; Utz, P. J.; Valone, F.; Steinman, L. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann. Neurol., 2008, 63 (5), 611-620.
139. ClinicalTrials.gov, Immunotherapy with BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis (NCT00103974). http://clinicaltrials.gov/ct2/show/NCT00103974 (accessed February 21, 2012).
140. ClinicalTrials.gov, BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis(NCT00382629). http://clinicaltrials.gov/ct2/show/NCT00382629 (accessed Febraury 21, 2012).